CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities:
Net income	$ 481,062	$ 248,031
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	51,999	38,551
Non-cash compensation expense	300,657	208,732
Losses on extinguishment of debt	16,927	10,787
Other non-cash charges and expenses, net	33,197	28,473
Deferred Taxes	(65,975)	(34,161)
Changes in assets and liabilites
(Increase) decrease in Sanofi, Bayer HealthCare, and trade accounts receivable	(462,943)	53,642
Increase in Inventories	(81,459)	(50,917)
Increase in prepaid expenses and other assets	(13,223)	(28,850)
Increase in deferred revenue	624,063	3,466
Increase in accounts payable, accrued expenses and other liabilities	164,652	76,506
Total adjustments	567,895	306,229
Net cash provided by operating activities	1,048,957	554,260
Cash flows from investing activities:
Purchases of marketable securities	(550,142)	(478,436)
Sales or maturities of marketable securities	265,995	216,478
Capital expenditures	(500,154)	(215,464)
Net cash used in investing activities	(784,301)	(477,422)
Cash flows from financing activities:
Proceeds (payments) in connection with facility and capital lease obligations	26,405	(810)
Repayments of convertible senior notes	(146,007)	(61,125)
Payments in connection with deduction of outstanding warrants	(523,487)	(143,041)
Proceeds from issuance of Common Stock	150,423	80,804
Payments in connection with Common Stock tendered for employee tax obligations	(71,673)	(175,866)
Excess tax benefit from stock-based compensation	305,551	334,146
Net cash (used in) provided by financing activities	(258,788)	34,108
Net increase in cash and cash equivalents	5,868	110,946
Cash and cash equivalents at beginning of period	648,719	535,608
Cash and cash equivalents at end of period	$ 654,587	$ 646,554